Kim De Veirman

2.9k total citations
69 papers, 2.1k citations indexed

About

Kim De Veirman is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Kim De Veirman has authored 69 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Molecular Biology, 39 papers in Hematology and 30 papers in Oncology. Recurrent topics in Kim De Veirman's work include Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (13 papers) and Immune cells in cancer (12 papers). Kim De Veirman is often cited by papers focused on Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (13 papers) and Immune cells in cancer (12 papers). Kim De Veirman collaborates with scholars based in Belgium, France and China. Kim De Veirman's co-authors include Eline Menu, Karin Vanderkerken, Elke De Bruyne, Ken Maes, Els Van Valckenborgh, Ivan Van Riet, Jinheng Wang, Sylvia Faict, Angelo Vacca and Maria Antonia Frassanito and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Kim De Veirman

64 papers receiving 2.0k citations

Peers

Kim De Veirman

HEMAT

ONCOL

IMMUN

Ken Maes Belgium

Yu-Tzu Tai United States

Max Jan United States

Petter Woll United Kingdom

Fotis Asimakopoulos United States

Armin Ehninger Germany

Ninib Baryawno United States

Samantha J. Busfield Australia

Vikas A. Gupta United States

François Lassailly United Kingdom

Ken Maes Belgium

Kim De Veirman

1.0k ×0.8

643 ×0.9

HEMAT

396 ×0.6

ONCOL

265 ×0.5

IMMUN

345 ×0.7

Citations per year, relative to Kim De Veirman Kim De Veirman (= 1×) peers Ken Maes

Countries citing papers authored by Kim De Veirman

Since Specialization

Citations

This map shows the geographic impact of Kim De Veirman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim De Veirman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim De Veirman more than expected).

Fields of papers citing papers by Kim De Veirman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim De Veirman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim De Veirman. The network helps show where Kim De Veirman may publish in the future.

Co-authorship network of co-authors of Kim De Veirman

This figure shows the co-authorship network connecting the top 25 collaborators of Kim De Veirman. A scholar is included among the top collaborators of Kim De Veirman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim De Veirman. Kim De Veirman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Théry, Fabien, Kim De Veirman, Karin Vanderkerken, et al.. (2025). Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy. Journal for ImmunoTherapy of Cancer. 13(4). e010673–e010673.

Olsen, Catharina, Nathan De Beule, Kim De Veirman, et al.. (2025). The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse. Journal of Experimental & Clinical Cancer Research. 44(1). 125–125. 2 indexed citations

Beule, Nathan De, Ann De Becker, Elke De Bruyne, et al.. (2024). AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies. Experimental Hematology and Oncology. 13(1). 99–99. 4 indexed citations

Vanderkerken, Karin, et al.. (2024). Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Experimental Hematology and Oncology. 13(1). 66–66. 17 indexed citations

Kancheva, Daliya, Rong Fan, Pauline M. R. Bardet, et al.. (2024). A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages. Journal of Hematology & Oncology. 17(1). 107–107. 2 indexed citations

Ates, Gamze, Sylvia Faict, Philip Vlummens, et al.. (2023). Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis. The Journal of Pathology. 260(2). 112–123. 12 indexed citations

Krasniqi, Ahmet, Janik Puttemans, Yana Dekempeneer, et al.. (2023). Targeted α-Therapy Using²²⁵Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. Journal of Nuclear Medicine. 64(5). 751–758. 21 indexed citations

Beck, Susanne, Vladimı́r Beneš, Hans Salwender, et al.. (2023). RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Frontiers in Immunology. 14. 1286700–1286700. 3 indexed citations

Deschoemaeker, Sofie, Geert Raes, Anke Maes, et al.. (2022). Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions. International Journal of Molecular Sciences. 23(2). 904–904. 30 indexed citations

10.

Vlummens, Philip, Anke Maes, Dirk Hose, et al.. (2022). Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis. Journal of Experimental & Clinical Cancer Research. 41(1). 45–45. 26 indexed citations

11.

Fan, Rong, Nathan De Beule, Anke Maes, et al.. (2022). The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Frontiers in Immunology. 13. 1016059–1016059. 15 indexed citations

12.

Caers, Jo, Guillaume Marcion, Kim De Veirman, et al.. (2022). Radiotheranostic Agents in Hematological Malignancies. Frontiers in Immunology. 13. 911080–911080. 8 indexed citations

13.

Vlummens, Philip, Kim De Veirman, Eline Menu, et al.. (2019). The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. Frontiers in Genetics. 10. 740–740. 5 indexed citations

14.

Maes, Anke, Ken Maes, Philip Vlummens, et al.. (2019). Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Blood Cancer Journal. 9(12). 87–87. 11 indexed citations

15.

Veirman, Kim De, Eline Menu, Ken Maes, et al.. (2018). Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters. 442. 233–241. 48 indexed citations

16.

Faict, Sylvia, Joséphine Muller, Kim De Veirman, et al.. (2018). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal. 8(11). 105–105. 125 indexed citations

17.

Veirman, Kim De, Nathan De Beule, Ken Maes, et al.. (2017). Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunology Research. 5(10). 839–846. 44 indexed citations

18.

Smedt, Eva De, Ken Maes, Stefaan Verhulst, et al.. (2017). Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. Cancer Research. 78(5). 1155–1168. 30 indexed citations

19.

Veirman, Kim De, Els Van Valckenborgh, Qods Lahmar, et al.. (2014). Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies. Frontiers in Oncology. 4. 349–349. 88 indexed citations

20.

Xu, Song, Kim De Veirman, Holly Evans, et al.. (2013). Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacologica Sinica. 34(5). 699–709. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact